Verteporfin
- Generic Name
- Verteporfin
- Brand Names
- Visudyne
- Drug Type
- Small Molecule
- Chemical Formula
- C41H42N4O8
- CAS Number
- 129497-78-5
- Unique Ingredient Identifier
- WU713D62N9
- Background
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
- Indication
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.
- Associated Conditions
- Subfoveal Choroidal Neovascularization (CNV)
- Associated Therapies
- -
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
- Conditions
- Chronic Central Serous Chorioretinopathy
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-09-28
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT00211445
- Locations
- 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- QLT Inc.
- Registration Number
- NCT00007969
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
- Conditions
- Brain and Central Nervous System TumorsMetastatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 24
- Registration Number
- NCT00002647
- Locations
- 🇺🇸
Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.